Alzheimer’s Conference Marked By Diversity Of Approaches
Executive Summary
Clinical trial results reported at AAIC demonstrate the variety of approaches, from novel to repurposed, in play as drugmakers attempt to delay the onset, slow the progression or even prevent the world’s second-most dreaded disease. It’s an arena in which first-in-human data can achieve rock star status.
You may also be interested in...
Piramal Imaging Adds New AD Tracers For Leadership In Neuroimaging Research
Piramal is working on what it claims is a well-rounded strategy for an international edge in the field of neuroimaging research. While it is adding newer tracers for detection of the root causes of Alzheimer’s disease, its first approved product Neuraceq is ready to hit the U.S. and European markets later this year.
Cipla Backs Chase For Alzheimer’s Drug Research
The top-tier Indian generic company is moving fast into unexpected research territories. In the latest announcement, Cipla said it will partly fund Chase’s Alzheimer’s programs and keep looking for more such opportunities.
Cipla Backs Chase For Alzheimer’s Drug Research
The top-tier Indian generic company is moving fast into unexpected research territories. In the latest announcement, Cipla said it will partly fund Chase’s Alzheimer’s programs and keep looking for more such opportunities.